Researchers at the University of Pittsburgh have found special high-risk cells in the fallopian tubes that may trigger ...

Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer (PROC) and continues to demonstrate ...

Researcher suggests compounds secreted by high-risk MSCs that are detectable in the bloodstream could act as biomarkers for ...

For some, menstruation is a life-giving gift — for others, it's sheer hell. For too long, women have been sitting in silent, ...

There are three main types of ovarian cancer: epithelial, germ cell, and stromal. Learn about each type’s defining ...

A new pill that promises to help endometriosis sufferers deal with the chronic disease’s debilitating symptoms was approved ...

Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues ...

For years, menopause has been framed as something that happens to women in their late 40s or early 50s. But new research published in NJP Women’s Health is challenging that assumption, revealing that ...

From taboo to top-of-mind—early intervention is key. But where to start? Read on for eight tips on how to prevent hair loss ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway ...

Antibody treatment which activates the patient's own immune system against cancer, known as immunotherapy, is increasingly ...

The University of Waterloo is enhancing student health services with the introduction of Dr. Sarah Connors, a naturopathic ...